FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897567843> ?p ?o ?g. }

• W2897567843 abstract "Benign prostatic hyperplasia (BPH) is a common condition in ageing men that may cause lower urinary tract symptoms (LUTS). Treatment aims are to relieve symptoms and prevent disease-related complications. Naftopidil is an alpha-blocker (AB) that has a high affinity for the A1d receptor that may have advantages in treating LUTS in this setting. This is an update of a Cochrane Review first published in 2009. Since that time, several large randomised controlled trials (RCTs) have been reported, making this update relevant.To evaluate the effects of naftopidil for the treatment of LUTS associated with BPH.We performed a comprehensive search using multiple databases (the Cochrane Library, MEDLINE, Embase, Scopus, LILAC, and Web of Science), trials registries, other sources of grey literature, and conference proceedings with no restrictions on the language of publication or publication status up to 31 May 2018 SELECTION CRITERIA: We included all parallel RCTs. We also included cross-over design trials.Two review authors independently classified and abstracted data from the included studies. We performed statistical analyses using a random-effects model and interpreted them according to the Cochrane Handbook for Systematic Reviews of Interventions. Primary outcomes were urological symptom scores, quality of life (QoL) and treatment withdrawals for any reason; secondary outcomes were treatment withdrawals due to adverse events, acute urinary retention, surgical intervention for BPH, and cardiovascular and sexual adverse events. We considered outcomes measured up to 12 months after randomisation as short term, and later than 12 months as long term. We rated the certainty of the evidence according to the GRADE approach.We included 22 RCTs with 2223 randomised participants across four comparisons for short-term follow-up. This abstract focuses on only two of four comparisons for which we found data since two comparators (i.e. propiverine and Eviprostat (phytotherapy)) are rarely used. One study comparing naftopidil to placebo did not report any relevant outcomes and was therefore excluded. There were no trials that compared to combination therapy with naftopidil or any 5-alpha reductase inhibitors (5-ARIs) to combination therapy with other ABs and any 5-ARIs.All included studies were conducted in Asian countries. Study duration ranged from four to 12 weeks. Mean age was 67.8 years, prostate volume was 35.4 mL, and International Prostate Symptom Score was 18.3. We were unable to perform any of the preplanned subgroup analyses based on age and baseline symptom score.Naftopidil versus tamsulosinBased on 12 studies with 965 randomised participants, naftopidil may have resulted in little or no difference in urological symptom score (mean difference (MD) 0.47, 95% confidence interval (CI) -0.09 to 1.04 measured on a scale from 0 to 35 with higher score representing increased symptoms), QoL (MD 0.11, 95% CI -0.09 to 0.30; measured on a scale from 0 to 6 with higher scores representing worse QoL), and treatment withdrawals for any reason (risk ratio (RR) 0.92, 95% CI 0.64 to 1.34; corresponding to 7 fewer per 1000 participants, 95% CI 32 fewer to 31 more). Naftopidil may have resulted in little to no difference in sexual adverse events (RR 0.54, 95% CI 0.24 to 1.22); this would result in 26 fewer sexual adverse events per 1000 participants (95% CI 43 fewer to 13 more). We rated the certainty of evidence as moderate for urological symptom score and low for the other outcomes.Naftopidil versus silodosinBased on five studies with 652 randomised participants, naftopidil may have resulted in little or no difference in the urological symptom scores (MD 1.04, 95% CI -0.78 to 2.85), QoL (MD 0.21, 95% CI -0.23 to 0.66), and treatment withdrawals for any reason (RR 0.80, 95% CI 0.52 to 1.23; corresponding to 26 fewer per 1000 participants, 95% CI 62 fewer to 32 more). We rated the certainty of evidence as low for all these outcomes. Naftopidil likely reduced sexual adverse events (RR 0.15, 95% CI 0.06 to 0.42; corresponding to 126 fewer sexual adverse events per 1000 participants, 95% CI 139 fewer to 86 fewer). We rated the certainty of evidence as moderate for sexual adverse events.Naftopidil appears to have similar effects in the urological symptom scores and QoL compared to tamsulosin and silodosin. Naftopidil has similar sexual adverse events compared to tamsulosin but has fewer compared to silodosin." @default.
• W2897567843 created "2018-10-26" @default.
• W2897567843 creator A5001861927 @default.
• W2897567843 creator A5002729731 @default.
• W2897567843 creator A5013203178 @default.
• W2897567843 creator A5014757964 @default.
• W2897567843 creator A5018863839 @default.
• W2897567843 creator A5037612453 @default.
• W2897567843 creator A5071905039 @default.
• W2897567843 date "2018-10-11" @default.
• W2897567843 modified "2023-09-23" @default.
• W2897567843 title "Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia" @default.
• W2897567843 cites W1158428179 @default.
• W2897567843 cites W134680794 @default.
• W2897567843 cites W1488647301 @default.
• W2897567843 cites W1489169544 @default.
• W2897567843 cites W1491256997 @default.
• W2897567843 cites W1496527706 @default.
• W2897567843 cites W1505739568 @default.
• W2897567843 cites W1563694713 @default.
• W2897567843 cites W1564432034 @default.
• W2897567843 cites W1583848026 @default.
• W2897567843 cites W1586377469 @default.
• W2897567843 cites W1594243544 @default.
• W2897567843 cites W1831194115 @default.
• W2897567843 cites W1890512450 @default.
• W2897567843 cites W1917454581 @default.
• W2897567843 cites W1961129264 @default.
• W2897567843 cites W1966898087 @default.
• W2897567843 cites W1968924642 @default.
• W2897567843 cites W1971867200 @default.
• W2897567843 cites W1978111452 @default.
• W2897567843 cites W1988727367 @default.
• W2897567843 cites W1991315347 @default.
• W2897567843 cites W2001207843 @default.
• W2897567843 cites W2001432092 @default.
• W2897567843 cites W2002004951 @default.
• W2897567843 cites W2005687876 @default.
• W2897567843 cites W2006615433 @default.
• W2897567843 cites W2009440132 @default.
• W2897567843 cites W2009567938 @default.
• W2897567843 cites W2019430383 @default.
• W2897567843 cites W2020529928 @default.
• W2897567843 cites W202053077 @default.
• W2897567843 cites W2020680714 @default.
• W2897567843 cites W2021505568 @default.
• W2897567843 cites W2032546889 @default.
• W2897567843 cites W2035593236 @default.
• W2897567843 cites W2037171825 @default.
• W2897567843 cites W2044618839 @default.
• W2897567843 cites W2045197041 @default.
• W2897567843 cites W2052655837 @default.
• W2897567843 cites W2053766817 @default.
• W2897567843 cites W2071152720 @default.
• W2897567843 cites W2076622798 @default.
• W2897567843 cites W2090132603 @default.
• W2897567843 cites W2091569598 @default.
• W2897567843 cites W2092630235 @default.
• W2897567843 cites W2096556143 @default.
• W2897567843 cites W2097724546 @default.
• W2897567843 cites W2101665942 @default.
• W2897567843 cites W2104675861 @default.
• W2897567843 cites W2106455438 @default.
• W2897567843 cites W2110120615 @default.
• W2897567843 cites W2119749032 @default.
• W2897567843 cites W2121759271 @default.
• W2897567843 cites W2125435699 @default.
• W2897567843 cites W2126930838 @default.
• W2897567843 cites W2132697170 @default.
• W2897567843 cites W2134236426 @default.
• W2897567843 cites W2167968554 @default.
• W2897567843 cites W2262550837 @default.
• W2897567843 cites W2290180479 @default.
• W2897567843 cites W2317074505 @default.
• W2897567843 cites W2354690888 @default.
• W2897567843 cites W2366055913 @default.
• W2897567843 cites W2409867059 @default.
• W2897567843 cites W2471811046 @default.
• W2897567843 cites W2483800985 @default.
• W2897567843 cites W2502961815 @default.
• W2897567843 cites W2510528922 @default.
• W2897567843 cites W2520329431 @default.
• W2897567843 cites W2528710770 @default.
• W2897567843 cites W2588681363 @default.
• W2897567843 cites W2603686761 @default.
• W2897567843 cites W2624813473 @default.
• W2897567843 cites W2729937958 @default.
• W2897567843 cites W2789588740 @default.
• W2897567843 cites W2916841405 @default.
• W2897567843 cites W2993539218 @default.
• W2897567843 cites W3022903699 @default.
• W2897567843 cites W30649991 @default.
• W2897567843 cites W4236163484 @default.
• W2897567843 cites W4236684284 @default.
• W2897567843 cites W5259485 @default.
• W2897567843 doi "https://doi.org/10.1002/14651858.cd007360.pub3" @default.
• W2897567843 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6516835" @default.
• W2897567843 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30306544" @default.
• W2897567843 hasPublicationYear "2018" @default.
• W2897567843 type Work @default.

• next